SOX2High showed a higher ratio in p16+ oropharyngeal cancer than p16−, but there was no statistically significant difference (76.1% vs. 63.4%, respectively, p = 0.157, Table 1). This evidence concerns the gene CDKN2A and oropharynx cancer.